Overview

A Study of KHK4827 in Subjects With Axial Spondyloarthritis (axSpA)

Status:
Completed
Trial end date:
2019-09-23
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of KHK4827 in axSpA (ankylosing spondylitis [AS] and non-radiographic axial spondyloarthritis [nr-axSpA]) subjects compared to placebo, as measured by the proportion of axSpA subjects achieving an Assessment of SpondyloArthritis international Society (ASAS) 40 response at week 16.
Phase:
Phase 3
Details
Lead Sponsor:
Kyowa Hakko Kirin Co., Ltd
Kyowa Kirin Co., Ltd.
Treatments:
Brodalumab